top of page

HOME > Analysis examples

Analysis examples

JMDC data can be used to conduct a variety of market research and hypothesis testing.

Case 1: The number of patients by age group and gender ratios

The number and percentage of patients by any segment, such as age and gender can be calculated.

②.png

<Analysis definition>

・Target : Patients diagnosed with [ICD10 level3][F90]hyperkinetic disorder in Feb 2020 ~ Jan 2021

・Database: JMDC payer database

Case 2: The number of medical consultations, the ratio of inpatients and outpatients

The number of medical institution visits and the ratio of inpatients/outpatients can be calculated.

③.png

<Analysis definition>

・Target : Patients diagnosed with [ICD10 level3][F90]hyperkinetic disorder in Feb 2020 ~ Jan 2021

・Database: JMDC payer database

Case 3: The number of patients by clinical department

The number of patients or share of a certain drug can be calculated by clinical department . 

スライド4.png

<Analysis definition>

・Target : Patients diagnosed with [ICD10 level3][F90]hyperkinetic disorder in Feb 2020 ~ Jan 2021

・Database: JMDC payer database

<Note>

・Top 9 departments are listed.

・Unknown department is excluded.

Case 4: Comorbidity rates

Complicating diseases in patients with any disease and the ratios can be obtained.

スライド5.png

<Analysis definition>

・Target : Patients diagnosed with [ICD10 level4][G470]Disorders of initiating and maintaining sleep [insomnias] in Sep 2019 ~ Aug 2020

・Database: JMDC payer database

<Note>

・Top 10 diseases are listed.

Case 5: Combination drug patterns

Combination drug patterns and the ratios can be obtained.

スライド6.png

<Analysis definition>

・Target : Patients diagnosed with [ICD10 level4][G470]Disorders of initiating and maintaining sleep [insomnias] and prescribed [ATC level3][N05B] HYPNOTICS/SEDATIVES / [N05C]TRANQUILLISERS in Sep 2019 ~ Aug 2020

・Database: JMDC payer database

Case 6: Average dose / length of prescription

The average dose and the average length of prescription by drug can be calculated.

スライド7.png

<Analysis definition>

・Target : Patients diagnosed with [ICD10 level3][F31]Bipolar affective disorder and prescribed [ATC level4][N06A3] Mood stabilisers / [N05A9]Conventional antipsychotics / [N05A1] Atypical antipsychotics in Sep 2018 ~ Aug 2019

・Database:JMDC payer database

Case 7: The actual situation of the new patient market

The disposition of patients, such as naive, continuous visit, and switch in any drug market can be obtained.

⑧.png

Case 8: Therapeutic continuation rates

The continuation rate of drug treatment, the factor contributing to the withdrawal of treatment, and the prescription of other drugs after withdrawal can be grasped.

スライド9.png

<Analysis definition>

・Target : Patients diagnosed with [ICD10 level3][K51]Ulcerative colitis and prescribed [Component]Adalimumab(Genetical Recombination) in Dec 2017 ~ Nov 2018

・Database: JMDC payer database

Case 9: Treatment flow

The flow of prescription patterns from the start of therapy can be captured.

The prescription timing of certain drug products and the drugs used in combination can be accurately determined.

Diabetes treatment flow

220104_Treatment flow (3).png
bottom of page